Inflammatory process in Alzheimer’s and Parkinson’s diseases: Central role of cytokines

Current Pharmaceutical Design

Volumn 22, Issue 5, 2016, Pages 541-548

  Alam, Qamre ^a   Alam, Mohammad Zubair ^a   Mushtaq, Gohar ^a   Damanhouri, Ghazi A ^a   Rasool, Mahmood ^a   Kamal, Mohammad Amjad ^a   Haque, Absarul ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Alzheimer s disease; Cytokines; Inflammation; Interleukin 1; Interleukin 6; Parkinson s disease; Transforming growth factor microglia; Tumor necrosis factor

Indexed keywords

CYTOKINE; DOPAMINE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CHRONIC INFLAMMATION; CYTOKINE RELEASE; HUMAN; INFLAMMATION; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; METABOLISM;

ALZHEIMER DISEASE; CYTOKINES; HUMANS; INFLAMMATION; PARKINSON DISEASE;

EID: 84958280013     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151125000300     Document Type: Article

References (125)

1. Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 2008; 13: 199-223.
2. Alam Q, Alam MZ, Karim S, et al. Nanotechnological approach to the management of Alzheimer disease and type 2 diabetes. CNS Neurol Disord Drug Targets 2014; 13: 478-86.
3. Fi a IG, Enciu AM, St noiu BP. New insights on Alzheimer's diease diagnostic. Rom J Morphol Embryol 2011; 52: 975-9.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
5. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383-421.
6. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
7. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances, Annu Rev Public Health 2002; 23: 213-31.
8. Stefanacci RG. The costs of Alzheimer's disease and the value of effective therapies. Am J Manag Care 2011; 17: 356-62.
9. Stefanacci RG. The costs of Alzheimer's disease and the value of effective therapies. Am J Manag Care 2011; 17: 356-62.
10. Kawajiri S, Saiki S, Sato S, Hattori N. Genetic mutations and functions of PINK1. Trends Pharmacol Sci 2011 32: 573-80.
11. Tabrez S, Jabir NR, Shakil S, et al. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug Targets 2012; 11: 395-409.
12. Khan W, Priyadarshini M, Zakai HA, Kamal MA, Alam Q. A brief overview of tyrosine hydroxylase and synuclein in the Parkinsonian brain. CNS Neurol Disord Drug Targets 2012; 11: 456-62.
13. Ruiz PJ, Catalán MJ, Carril JM. Initial motor symptoms of Parkinson disease. Neurologist 2011; 17: 18-20.
14. Booij J, Bergmans P, Winogroolzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I] Fp-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson’s disease. Synapse 2001; 39: 101-8.
15. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 2005; 92: 201-5.
16. Stacy MA, Murck H, Kroenke K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 57-61.
17. Hwang DY, Ardayfio P, Kang UJ, Semina EV, Kim KS. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 2003 114: 123-31.
18. Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin 1996; 14: 317-35.
19. Zhang Z, Roman GC. Worldwide occurrence of Parkinson’s disease: an updated review. Neuroepidemiology 1993 12: 195-208.
20. Nedjadi T, Haque A, Alam Q, et al. Genomic approach towards Molecular Linkage in between Alzheimer’s disease and type 2 Diabetes. CNS Neurol Disord Drug Targets 2014; 13: 203-12.
21. Ahmed F, Ansari JA, Ansari ZE, et al. Molecular bridge: Connecting Diabetes type II and Alzheimer’s disease. CNS Neurol Disord Drug Targets 2014; 13: 312-21.
22. Courtney C, Farrell D, Gray R, et al. AD2000 Collaborative Group long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
23. Chen H, Zhang SM, Hernan MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003; 60: 1059-64.
24. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29: 357-65.
25. Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009; 89: 277-87.
26. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia is positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
27. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998; 13: 221-7.
28. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
29. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003; 106: 518-26.
30. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151-4.
31. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-alpha and IL-6 with ageing and Parkinsonism. Acta Neurol Scand 1999; 100: 34-41.
32. Finch CE, Morgan TE. Systemic inflammation, infection, Apo Ealleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 2007; 4: 185-9.
33. Heneka MT, O’Banion MK. Inflammatory processesin Alzheimer’s disease. J Neuroimmunol 2007; 184: 69-91.
34. Barger SW, Harmon AD. Microglial activation by alzhelmer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388: 878-1.
35. Owens T, Babcock AA, Millward JM, ToftHansen H. Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Br Res Rev 2005; 48: 178-84.
36. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 2003; 27: 325-55.
37. Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neuro-filament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2014; 85: 274-8.
38. Lindberg C, Hjorth E, Post C, Winblad B, Schultzberg M. Cytokine production by a human microglial cell line: effects of amyloid and -melanocyte-stimulatinghormone. Neurot Res 2005; 8: 267-76.
39. Nyoman G, Darmadipura S. The Role of Microglia as Prime Component of CNS Immune System in Acute and Chronic Neuroin-flammation. Folic Med Indonesiana 2007; 43: 54-58.
40. Long-Smith CM, Sullivan AM, Nolan YM. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009; 89: 277-87.
41. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia is positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
42. Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin 6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonianpatients. Neurosci Lett 1994a; 180: 147-50.
43. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999; 57: 563-81.
44. Le WD, Rowe DB, Xie W. Activated microglia induce dopaminergic cell injury in vitro. XIII International Congress on Parkinson’s disease. Parkinson Relat Disord Vancouver 1999; 5: 19.
45. liu B, jau-shyong H. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Therap 2003; 304: 7.
46. Bronstein DM, Perez-Otano I, Sun V, et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 1995; 704: 112-6.
47. Araki E, Forster C, Dubinsky JM, Ross ME, Iadecola C. Cyclooxygenase-2 inhibitor NS-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 2001; 32: 2370-5.
48. Itzhak Y, Martin JL, Ali SF. Methamphetamine- and 1-methyl-4-phenyl- 1, 2, 3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in inducible nitric oxide synthase-deficient mice. Synapse 1999; 34: 305-12.
49. Liberatore GT, Jackson-Lewis V, Vukosavic S, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999; 5: 1403-9.
50. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000; 74: 2213-6.
51. Qin L, Liu YX, Cooper CL, Liu B, Wilson B, Hong JS. The role of microglia in amyloid (1-42) toxicity to cortical and mesencephalic neurons. J Neurochem 2002; 293: 617-9.
52. Fujiwara N, Kobayashi K. Macrophages in inXammation. Curr Drug Targets InXamm Allergy 2005; 4: 281-6.
53. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
54. Qiu WQ, Walsh DM, Ye Z. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-8.
55. Chesneau V, Vekrellis K, Rosner MR, Selkoe DJ. Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization. Biochem J 2000; 351: 509-16.
56. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl 2000; 70: 373-81.
57. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11: 999-1016.
58. Griffin WST, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leuko Biol 2002; 72: 233-8.
59. Cacquevel M, Lebeurrier N, Chéenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004; 5: 529-34.
60. Dinarello CA. The IL-1 family and inflammatory diseases. Clin Exp Rheumatol 2002; 20: S1-13.
61. Saito T, Yasukawa K, Suzuki H. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J Immunol 1991; 147: 168-73.
62. Satoh T, Nakamura S, Taga T. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol 1988; 8: 3546-9.
63. Rodney R, Dietert RW. The role of interleukin-1 in neuroin flammation and Alzheimer disease: an evolving perspective. J Neurosci 2008; 29: 1846-54.
64. Dinarello CA. Biological basis for IL-1 in disease. Blood 1996; 87: 2095-147.
65. Hetier E, Ayala J, Denefle P, et al. Brain macrophages synthesize interleukin-1, and interleukin- 1 mRNAs in vitro. J Neurosci Res 1988; 21: 391-7.
66. Vitkovic L, Bockaert J, Jacque C. “Inflammatory” cytokines: neuromodulators in normal brain? J Neurochem 2000; 74: 457-71.
67. Griffin WST, Stanley LC, Ling C, et al. Brain interleukin 1, and S-100 immunoreactivity are elevated in Down syndrome, and Alzheimer disease. Proc. Natl Acad Sci USA 1989; 86: 7611-5.
68. Sheng JG, Mrak RE, Griffin WST. Microglial interleukin-1_ expression in brain regions in Alzheimer’sdisease: correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1995; 21: 290-301.
69. Sheng JG, Griffin WST, Royston CM, Mrak RE. Distribution of IL-1-immunoreactive microglia in cerebral cortical layers: implications for neuritic plaque formation in Alzheimer’s disease. Neuropathol Appl Neurobiol 1998; 24; 278-83.
70. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angaretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal, and glial cells: modulation by interleukin 1. Brain Res Mol Brain Res 1992; 16: 128-34.
71. Goldgaber D, Harris HW, Hla T, et al Interleukin 1 regulates synthesis of amyloid _-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989; 86: 7606-10.
72. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists, and interleukin 1 regulate processing, and secretion of the Alzheimer A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992; 89: 10075-8.
73. Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein, and modulation by apolipoprotein E. Nature 1997; 388: 878-81.
74. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. Cytokine production by human fetal microglia, and astrocytes. Differential induction by lipopolysaccharide and IL1. J Immunol 1993; 150: 2659-67.
75. Sebire G, Emilie D, Wallon C, et al. In vitro production of IL-6, IL-1, and TNF- by human embryonic microglial, and neural cells. J Immunol 1993; 150: 1517-23.
76. Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003; 53: S26-38.
77. Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic mtargets for neurodegenerative diseases. Trends Pharmacol Sci 2012; 33: 295-303.
78. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996; 47: S161-70.
79. Izumi Y, Sawada H, Yamamoto N, et al. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J Neurosci Res 2005; 82: 126-37.
80. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996; 334: 1717-25.
81. Idriss HT, Naismith JH. TNF-and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50: 184-95.
82. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
83. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 1997; 385: 729-33.
84. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S. Histamine antagonizes tumor necrosis factor(TNF) signalling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003; 278: 21751-60.
85. Sharma V, Thakur V, Singh SN, Guleria R. Tumor necrosis factor and Alzheimer’s disease: a cause and consequence relationship. Bull Clin Psychopharmacol 2012; 22: 86-97.
86. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994; 6: 341-60.
87. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999; 10: 119-30.
88. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997; 778: 265-71.
89. Butterfield DA, Drake J., Pocernich C, Castegna A. Evidence of oxidativedamage in Alzheimer’s disease brain: central role for amyloid betapeptide. Trends Mol Med 2001; 7: 548-54.
90. Goodwin JL, Uemura E, Cunnick JE. Microglial release of nitric oxide by the synergistic action of-amyloid and IFN-α Brain Res 1995; 692: 207-14.
91. Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNF alpha. Science 2002; 295: 2282-5.
92. Pickering M, Cumiskey D, O'Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005; 90: 663-70.
93. Domonkos A, Udvardy A, Laszlo L, Nagy T, Duda E. Receptor-like properties of the 26 kDa transmembrane form of TNF. Eur Cytokine Netw 2001; 12: 411-9.
94. Nishimura M, Mizuta I, Mizuta E, et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 2001; 311:4.
95. Kruger R, Hardt C, Tschentscher F, et al. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J Neural Transm 2000; 107: 553-62.
96. Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol 2007; 64: 836-40.
97. Dijke PT, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004; 29: 265-73.
98. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-regulation of immune responses. Annu Rev Immunol 2006; 24: 99-146.
99. Hamaguchi T, Okino S, Sodeyama N, et al. Association of a polymorphism of the transforming growth factor-b1 gene with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 2005; 76: 696-9.
100. Caraci F, Spampinato S, Sortino MA, et al. Dysfunction of TGF-1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell Tissue Res 2012; 347: 291-301.
101. Taipale J, Saharinen J, Keski-Oja J. Extracellular matrixaassociated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res 1998; 75: 87-134.
102. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 1999; 8: 93-97.
103. Syrris P, Carter ND, Metcalfe JC, et al. Transforming growth factor- 1 gene polymorphisms and coronary artery disease. Clin Sci 1998; 5: 659-67.
104. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor- beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-20.
105. Chao CC, Hu S, Frey WH, Ala TA, Tourtellotte WW, Peterson PK. Transforming growth factor beta in Alzheimer’s disease. Clin Diag Lab Immunol 1994; 1: 109-10.
106. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-beta in Alzheimer’s disease. Neurology 1995; 45: 1561-9.
107. Van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993; 4: 69-72.
108. Masliah E, Ho G, Wyss-Coray T. Functional role of TGFbeta in Alzheimer’s disease microvascular injury: lessons from transgenic mice. Neurochem Int 2001; 39: 393-400.
109. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer R, Nagatsu T. Transforming growth factor- l 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995; 193: 129-32.
110. Carvey PM, Ptak LR, Nath ST, et al. Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures. Exp Neurol 1993; 120: 149-52.
111. Yu SJ, Lo ES, Cochran EJ, et al. Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephaiic culture. Exp Neurol 1994; 126: 15-24.
112. Wyss-Coray T. TGF-Pathway as a Potential Target in Neurode-generation and Alzheimer’s. Curr Alzheimer Res 2006; 3: 191-5.
113. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl 2006; 70: 373-81.
114. Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997; 15: 307-39.
115. Gadient RA, Otten UH. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997; 52: 379-90.
116. O’Hara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of hematopoietic lineage. Nature 1987; 325: 537-40.
117. Vallieres L, Rivest S. Regulation of the genes encoding IL-6, its receptor, and gp130 in the rat brain in response to the immune acti-vator lipopolysaccharide and the proinflammatory cytokine IL-1beta. J Neurochem 1997; 69: 1668-83.
118. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989; 19: 689-94.
119. Marz P, Cheng JG, Gadient RA. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA 1998; 95: 3251-6.
120. Campbell IL. Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Rev 1998; 26: 327-36.
121. Gadient RA, Otten UH. IL-6-a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997; 52: 379-90.
122. Gruol DL, Nelson TE. Physiological and pathological roles of IL-6 in the central nervous system. Mol Neurobiol 1997; 15: 307-39.
123. Murphy PG, Altares M, Gauldie J, Richardson PM. IL-6 promotes survival of sensory neurons. Neuroscience 1997; 23: 890.
124. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recom-binant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol 1994; 153: 3811-21.
125. Czlonkowska A, Jastrzebska IK, Cztonkowski A. Immune processes in the pathogenesis of Parkinson’s disease—a potential role for microglia and nitric oxide. Med Sci Monit 2002; 8: 165-77.